These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 24612466

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Future treatment of patients with HCV cirrhosis.
    Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.
    Liver Int; 2012 Feb; 32 Suppl 1():113-9. PubMed ID: 22212581
    [Abstract] [Full Text] [Related]

  • 23. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F.
    Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
    [Abstract] [Full Text] [Related]

  • 24. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
    Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hézode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Lédinghen V, ANRS CO20 CUPIC Study Group.
    J Viral Hepat; 2015 Dec; 22(12):1002-10. PubMed ID: 26216230
    [Abstract] [Full Text] [Related]

  • 25. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á, García-González X, Rodríguez-González CG, Ochoa-Palominos A, Sanjurjo-Sáez M, Clemente-Ricote G.
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [Abstract] [Full Text] [Related]

  • 26. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [Abstract] [Full Text] [Related]

  • 27. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Aug; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 28. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D, ESCMID European Study Group on Viral Hepatitis.
    Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
    [Abstract] [Full Text] [Related]

  • 29. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [Abstract] [Full Text] [Related]

  • 30. [Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
    Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R, Buti M, López J, Calleja JL, en representación del grupo de investigadores del estudio LEAD-IN.
    Gastroenterol Hepatol; 2015 Nov; 38(9):517-24. PubMed ID: 25976446
    [Abstract] [Full Text] [Related]

  • 31. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 32. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M.
    World J Gastroenterol; 2015 May 14; 21(18):5496-504. PubMed ID: 25987772
    [Abstract] [Full Text] [Related]

  • 33. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J.
    Antivir Ther; 2015 May 14; 20(2):185-92. PubMed ID: 24941012
    [Abstract] [Full Text] [Related]

  • 34. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M, Von Wichmann MA, Van den Eynde E, Navarro J, Cifuentes C, Murillas J, Veloso S, Martínez-Rebollar M, Guardiola JM, Jou A, Gómez-Sirvent JL, Cervantes M, Pineda JA, López-Calvo S, Carrero A, Montes ML, Deig E, Tapiz A, Ruiz-Mesa JD, Cruceta A, de Lazzari E, Mallolas J.
    Int J Infect Dis; 2016 Dec 14; 53():46-51. PubMed ID: 27815225
    [Abstract] [Full Text] [Related]

  • 35. Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
    Kwo PY.
    Liver Int; 2012 Feb 14; 32 Suppl 1():39-43. PubMed ID: 22212570
    [Abstract] [Full Text] [Related]

  • 36. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA.
    J Infect; 2013 Jul 14; 67(1):59-64. PubMed ID: 23542783
    [Abstract] [Full Text] [Related]

  • 37. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.
    Antivir Ther; 2011 Jul 14; 16(5):695-704. PubMed ID: 21817191
    [Abstract] [Full Text] [Related]

  • 38. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
    Swiss Association for the Study of the LiverDivision of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland..
    Swiss Med Wkly; 2012 Jul 14; 142():w13516. PubMed ID: 22367957
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.
    Park C, Jiang S, Lawson KA.
    J Clin Pharm Ther; 2014 Feb 14; 39(1):14-24. PubMed ID: 24237070
    [Abstract] [Full Text] [Related]

  • 40. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
    Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, Labbett W, Smith C, Velazquez C, Tanwar S, Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T.
    Antiviral Res; 2014 May 14; 105():112-7. PubMed ID: 24594347
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.